Obicetrapib Cuts Coronary Events 32% in High-Risk Heart Patients
A pooled analysis of 2,884 patients finds obicetrapib significantly reduces coronary events after 6 months, with striking lipid improvements.
Cardiovascular health, heart failure, atherosclerosis, and cardiac research
460 articles
A pooled analysis of 2,884 patients finds obicetrapib significantly reduces coronary events after 6 months, with striking lipid improvements.
In 2,040 coronary angiography patients, OxPL-apoB predicted MI-free survival but showed no link to platelet reactivity, implicating Lp(a) as the key mediator.
A pill-form GLP-1 receptor agonist significantly reduced multiple cardiovascular risk markers in both T2D and obesity patients over 26–36 weeks.
A proteomics screen of 2,920 plasma proteins identifies a 17-protein score that lifts heart failure prediction accuracy to 0.833 C-index in type 2 diabetes patients.
Leading cardiologists from Brigham and Johns Hopkins debate which imaging tool better directs primary prevention decisions.
Dr. Terry Simpson brings personal experience with FH, tirzepatide, and statins to a blunt takedown of health misinformation.
New molecular analysis reveals cardiac sarcoidosis triggers self-targeting antibodies against a desmosome protein, explaining its overlap with arrhythmic heart disease.
A large genome-first study reveals critical gaps in familial hypercholesterolemia diagnosis for people of African ancestry due to variant classification bias.
A comprehensive review reveals tirzepatide improves blood pressure, lipids, liver fat, kidney function, and slashes 10-year cardiovascular risk by up to 23.5%.
A novel CTSL–Notch1–CUX1 pathway drives endothelial senescence and atherosclerotic plaque buildup, revealing fresh drug targets.
A post hoc analysis of the CLEAR Outcomes trial finds bempedoic acid significantly reduces DVT and pulmonary embolism risk.
A new JAMA Cardiology analysis warns that rising temperatures and a growing elderly population are converging to produce an unprecedented cardiac emergency.